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Abstract: Delphinidin is a polyphenolic compound found in many brightly colored fruits and vegetables. Delphinidin is also the major 
bioactive component found in many dietary supplements that are currently consumed as complementary cancer medicine including 
pomegranate extract. The purpose of the current study was to determine the in vitro biological effects of delphinidin on established 
breast cancer cell lines of varying molecular subtypes in comparison to non-transformed breast epithelial cells. We examined cell pro-
liferation, apoptosis, and growth inhibition in response to delphinidin using a tetrazolium salt-based assay, DNA fragmentation assay, 
and anchorage-independent growth assay. In comparison to vehicle control, delphinidin inhibited proliferation (P , 0.05), blocked 
anchorage-independent growth (P , 0.05), and induced apoptosis (P , 0.05) of ER-positive, triple negative, and HER2-overexpressing 
breast cancer cell lines with limited toxicity to non-transformed breast epithelial cells. MAPK signaling was partially reduced in triple 
negative cells and ER-negative chemically transformed MCF10A cells after treatment with delphinidin. In addition, delphinidin induced 
a significant level of apoptosis in HER2-overexpressing cells in association with reduced HER2 and MAPK signaling. Since delphinidin 
is often consumed as a complementary cancer medicine, the effect of delphinidin on response to specific HER2-targeted breast cancer 
therapies was examined by proliferation assay. Results of these drug combination studies suggested potential antagonism between 
delphinidin and HER2-directed treatments. In summary, the data presented here suggest that single agent delphinidin exhibits growth 
inhibitory activity in breast cancer cells of various molecular subtypes, but raise concerns regarding potential drug antagonism when 
used in combination with existing targeted therapies in HER2-overexpressing breast cancer.
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Introduction
Breast  cancer  is  the  most  common  malignancy 
amongst women in the United States, and the sec-
ond leading cause of cancer-related death in women.1 
Standard  treatments  include  cytotoxic  non-specific 
chemotherapy  and  therapies  targeted  against  the 
estrogen receptor (ER) or HER2. The five year sur-
vival rate for patients with early-stage breast cancer 
who receive treatment is extremely high. However, a 
subset of patients with advanced stage breast cancer 
may suffer recurrence within 10 years of treatment. 
Overall, it is estimated that 11 percent of women with 
breast cancer will have a recurrence at five years and 
20 percent at 10 years post-treatment. Gene expres-
sion profiling has been used to separate breast cancers 
into  distinct  molecular  subtypes,  which  may  have 
prognostic  value.2  Recurrence  rates  for  luminal  A 
breast cancers have been reported to be lower (5-year 
recurrence rate of approximately 8%) versus subtypes 
that overexpress HER2 or have basal-like features or 
triple negative phenotype (15%–20% 5-year recur-
rence rate).2–5 Despite the availability of effective ER- 
and HER2-targeted therapies, drug discovery efforts 
continue to seek additional agents that may inhibit 
breast cancer cell growth, particularly drugs that may 
be effective in multiple subtypes of breast cancer.
Recent drug discovery efforts have included exam-
ining  naturally  occurring  polyphenolic  compounds 
because  of  their  ability  to  inhibit  proliferation  and 
induce apoptosis of breast cancer cells. The major class 
of polyphenols consumed by humans, due to their abun-
dance in fruits and vegetables, are the anthocyanidins.6 
Delphinidin, one of the major anthocyanidins found 
in foods commonly consumed in the American diet, 
is a diphenylpropane-based polyphenolic ring struc-
ture that carries a positive charge in its central ring.7 
  Delphinidin has been shown to inhibit proliferation 
and induce apoptosis in many different cancer mod-
els  including  colon,  uterine,  breast,  and  prostate.8–11 
  Potential use of delphinidin as a cancer chemopreven-
tion agent has been suggested by studies showing its 
ability to inhibit transformation of JB6 mouse cells 
induced  by  12-O-tetradecanoylphorbol-13-acetate 
(TPA), EGF, or H-Ras.12,13 In addition, the cancer pre-
vention and   therapeutic actions of delphinidin have 
been associated with inhibition of EGFR and vascular 
endothelial growth factor receptor 2 (VEGFR2) tyrosine 
kinase activity,13 and with   inhibition of   signaling from 
MAPK, nuclear   factor-kappa B (NF-kB), and activator 
protein-1 (AP-1).13,14
The  purpose  of  the  current  study  was  to  deter-
mine the in vitro biological effects of delphinidin on 
breast cancer cell lines of different molecular sub-
types, including HER2-overexpressing, ER-positive, 
and triple negative in comparison to non-transformed 
breast epithelial cells. We present data indicating that 
delphinidin blocks proliferation and survival of ER-
positive, triple negative, and HER2-overexpressing 
breast cancer cell lines with limited toxicity to non-
transformed breast epithelial cells. MAPK signaling 
is partially reduced by delphinidin in triple negative 
HCC1806 cells and ER-negative chemically trans-
formed  MCF10A  cells.  In  addition,  delphinidin-
mediated  apoptosis  of  HER2-overexpressing  cells 
is associated with inhibition of HER2 and MAPK 
  signaling. However, drug combination studies sug-
gest potential antagonism between delphinidin and 
existing HER2-directed treatments. In summary, the 
data  presented  here  suggest  that  single  agent  del-
phinidin exhibits growth inhibitory activity in breast 
cancer cells of various molecular subtypes, but raise 
concerns regarding potential drug antagonism when 
used as a complementary cancer medicine in HER2-
overexpressing breast cancer.
Materials and Methods
Materials
Delphinidin was purchased from Indofine Chemical 
(Hillsborough, NJ), and dissolved in DMSO at a final 
concentration of 10 mg/mL. PhIP (2-amino-1-methyl-
6-phenylimidazo[4,5-b]pyridine)  was  purchased 
from Toronto Research Chemicals and dissolved in 
DMSO at final concentration 500 µM. Lapatinib was 
purchased from Santa Cruz, Biotechnology, and dis-
solved in DMSO at a stock concentration of 10 mM. 
Herceptin  (Trastuzumab)  was  obtained  from  the 
Emory Winship Cancer Institute pharmacy and dis-
solved  in  sterile  water  at  a  stock  concentration  of 
20 mg/mL.
Cell culture
HCC1806, MDA231, MDA468, SKBR3, MDA453, 
BT474,  and  MCF7  breast  cancer  cell  lines  and 
MCF10A  non-transformed  breast  epithelial  cell 
line  were  purchased  from ATCC  (Manassas,  VA). 
HCC1806  was  maintained  in  RPMI  supplemented growth inhibitory effects of delphinidin in breast cancer
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with 10% fetal calf serum (FCS) and 1% penicillin/
streptomycin. MCF10A was maintained in DMEM/
F12 with 5% horse serum, 20 ng/mL EGF, 10 µg/mL 
insulin,  and  0.5  µg/mL  hydrocortisone.  MCF10A.
DMSO and MCF10A.PhIP cells were maintained in 
regular MCF10A cell culture media but were further 
supplemented with DMSO or 100 nM PhIP, respec-
tively, for more than three months. PhIP was added 
to media of cells, as it has previously been shown 
to  promote  mammary  carcinogenesis.15  MDA231, 
MDA468,  SKBR3,  MDA453,  BT474,  and  MCF7 
were  maintained  in  Dulbecco’s  modified  Eagle’s 
medium  supplemented  with  10%  FCS  and  1% 
  penicillin/streptomycin. All cells were incubated at 
37 °C with 5% CO2 in humidified incubators.
Cell proliferation assay
Cells were plated at 3000 per well in 96-well format, 
and treated with delphinidin versus DMSO control 
corresponding  to  the  volume  of  DMSO  found  in 
the  highest  delphinidin  concentration.  For  another 
experiment, cells were treated with delphinidin, tras-
tuzumab, lapatinib, combination trastuzumab plus del-
phinidin, or lapatinib plus delphinidin. After 6 days of 
treatment, proliferation was measured using 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS), 
as directed by the manufacturer (Promega). All treat-
ments were done in six replicates.
DnA fragmentation assay
Cells were plated at 10,000 cells per well in 6-well 
format and treated with delphinidin for 48 h. Protein 
lysates  were  obtained  and  analyzed  for  cytoplas-
mic  histone-associated  DNA  fragments  (mononu-
cleosomes  and  oligonucleosomes)  representative 
of apoptosis using the Cell Death Detection ELISA 
(Roche, Indianapolis, IN) according to manufacturer 
guidelines. Absorbance  was  measured  at  405  nm. 
The fold change in absorbance, which was indicative 
of  DNA  fragmentation,  was  determined  per  treat-
ment group relative to the absorbance of the control 
DMSO group per cell line. Experiments were done in 
duplicate.
Anchorage-independent growth
Cells  were  plated  in  matrigel  (BD  Biosciences; 
  Franklin Lakes, NJ) diluted 3:1 (media:matrigel). 
Media   containing delphinidin or DMSO control at the 
same volume found in the highest dose of delphinidin 
was added to the matrigel-cell culture. Media plus drug 
or control was changed twice a week for approximately 
3–4 weeks. Photographs were taken with an Olympus 
IX50 inverted microscope at 4× magnification.   Matrigel 
was then digested using dispase (BD Biosciences), and 
viable cells were counted by trypan blue exclusion. All 
treatments  were  done  in  duplicate,  and  experiments 
were performed on at least two separate occasions.
Migration assay
Confluent monolayer cultures of SKBR3 cells were 
scratched down the center with a pipet tip to create a 
“wound”. Cells were then treated with 50 µg/mL del-
phinidin or DMSO at the same volume as that found 
in the dose of delphinidin. Photos were taken with 
an Olympus IX50 microscope at 4× magnification at 
0 hours (h) and 48 h after treatment. All treatments 
were done in duplicate, and experiments were per-
formed on at least two separate occasions.
immunoblotting
Cells  were  lysed  in  RIPA  buffer  (Cell  Signaling; 
Danvers,  MA),  which  includes  0.1%  NP40,  sup-
plemented  with  protease  and  phosphatase  inhibi-
tor cocktails (Sigma; St. Louis, MO). Total protein 
extracts (50 µg) were run on SDS-PAGE and immu-
noblotted using the following antibodies at the indi-
cated dilutions: HER2 monoclonal Ab-3 and p-T180/
Y182 p38MAPK were from EMD Chemicals, San 
Diego, CA and were used at 1:1000 each; from Cell 
Signaling, p-Ser 473-Akt (monoclonal 587F11), and 
polyclonal antibodies against Akt, p-Thr202/Tyr204 
p42/p44  MAPK,  total  p42/p44  MAPK  at  1:1000, 
and polyclonal p-Tyr1248 HER2 used at 1:200; from 
Santa Cruz Biotech, p-JNK (G7) used at 1:200 and 
survivin monoclonal D8 at 1:500; β-actin monoclo-
nal AC-15 (Sigma-Aldrich) at 1:10,000. Secondary 
antibodies were chosen according to the species of 
origin of the primary antibody. Protein bands were 
detected using the Odyssey Imaging System (Li-Cor 
Biosciences). Each Western blot was performed twice 
for reproducibility.
Statistical analysis
Results were analyzed using single factor ANOVA 
tests to assess statistical significance of differences Ozbay and nahta
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between multiple breast cancer cell lines or between 
multiple doses. Student’s t-test was used to determine 
significance  between  a  single  treatment  group  and 
control. Values of P , 0.05 were considered statisti-
cally significant.
Results
Delphinidin inhibits proliferation and 
induces apoptosis of breast cancer cells
A panel of seven breast cancer cell lines was treated 
with increasing concentrations of delphinidin ranging 
from 12.5 µg/mL to 100 µg/mL for 6 d. These con-
centrations were chosen based on published studies 
using similar doses. Proliferation was determined by 
MTS assay, and is expressed as a percentage of con-
trol DMSO-treated cells per cell line (Fig. 1A). The 
majority of cell lines demonstrated 50% inhibition of 
proliferation  at  approximately 50  µg/mL,  although 
MDA468 cells were slightly less sensitive with only 
20%–30% inhibition at 50 µg/mL. Molecular sub-
type with respect to ER or HER2 expression status 
did not appear to predict for response. In contrast to 
the majority of breast cancer cell lines, proliferation 
of the non-transformed immortalized breast epithelial 
cell line MCF10A was not significantly inhibited by 
delphinidin except at the highest concentration.
To determine if delphinidin-mediated inhibition of 
proliferation was a reflection of apoptosis, cells were 
treated with 25 µg/mL or 50 µg/mL delphinidin for 48 
h, since these are the lowest doses at which delphinidin 
showed anti-proliferative effects. Colorimetric ELI-
SA-based detection of histone-complexed DNA frag-
ments (mono- and oligonucleosomes) demonstrated 
that 50 µg/mL delphinidin induced significant DNA 
fragmentation in breast cancer cell lines (Fig. 1B), 
confirming induction of apoptosis. Similar to the pro-
liferation assay, MDA468 cells showed lower sensi-
tivity to delphinidin versus other cell lines. However, 
in contrast to delphinidin-mediated inhibition of pro-
liferation which showed no dependence on molecu-
lar  subtype,  delphinidin  induced  the  highest  level 
of apoptosis (4- to 6-fold) in HER2-overexpressing 
lines SKBR3 and BT474 versus 2-fold in triple nega-
tive lines HCC1806 and MDA231. Delphinidin did 
not promote apoptosis in non-transformed MCF10A 
cells, consistent with results from proliferation assays. 
In  addition,  delphinidin  suppressed  expression  of 
the anti-apoptotic protein survivin in breast cancer 
cell lines but not in MCF10A cells (Fig. 1C). These 
results indicate that delphinidin inhibits proliferation 
and induces apoptosis in breast cancer cell lines of 
varying molecular subtype, with limited toxicity to 
non-cancerous breast epithelial cells.
Delphinidin blocks anchorage-
independent growth and migration  
of breast cancer cells
Anchorage-independent growth is considered to be 
an in vitro indicator of the invasive potential of can-
cer cells. Triple negative MDA231 and MDA468, 
and HER2-overexpressing SKBR3 and BT474 cells 
were plated in matrigel and treated with 50 µg/mL or 
100 µg/mL of delphinidin for 3 to 4 weeks. All cell lines 
showed statistically significant reduction in anchor-
age-independent growth in response to delphinidin 
versus vehicle control and across all doses (Fig. 2A). 
Although delphinidin showed limited effects on pro-
liferation and apoptosis of MDA468 cells, anchor-
age-independent  growth  was  inhibited  in  this  line 
as significantly as in other breast cancer lines, sug-
gesting that delphinidin may inhibit invasiveness of 
breast cancer cells. In addition to anchorage-indepen-
dent growth, cell migration in response to delphini-
din  was  assessed.  SKBR3  HER2-overexpressing 
breast cancer cells were plated as confluent cultures, 
and scratched down the middle to create an open 
area. Cells were then treated with DMSO control or 
50 µg/mL delphinidin for 48 h (Fig. 2B).   Delphinidin 
inhibited migration of SKBR3 cells. Collectively, 
these assays indicate that delphinidin blocks anchor-
age-independent growth and migration, suggesting 
that  delphinidin  may  suppress  the  highly  invasive 
potential of breast cancer cells of the triple negative 
or HER2-overexpressing molecular subtype.
Delphinidin reduces heR2 and MAPK 
signaling in breast cancer cells
SKBR3  HER2-overexpressing  breast  cancer  cells 
were  treated  with  50 µg/mL delphinidin for 6, 24, 
or  48  h,  since  this  is  the  dose  at  which  approxi-
mately 50% inhibition of proliferation was achieved. 
Protein  lysates  were  examined  for  phosphorylated 
and  total  HER2, Akt,  and  Erk1/2  (Fig.  3 A).  Del-
phinidin  showed  dramatic  inhibition  of  HER2  sig-
naling with reduced phosphorylation of HER2, Akt, 
and  Erk1/2.    Signaling  through  MAPK  appeared  to growth inhibitory effects of delphinidin in breast cancer
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Figure 1. Delphinidin inhibits proliferation of breast cancer cells with limited toxicity to non-transformed cells. (A) Breast cancer cells and non-transformed 
mammary epithelial cell line MCF10A were treated with 2-fold serial dilutions of delphinidin ranging from 12.5 µg/mL to 100 µg/mL. Control (C) cells were 
treated with DMSO at the volume found in the highest dose of delphinidin. After 6 days, proliferation was measured by MTS assay (Promega; Madison, 
Wi). Treatments were done in 6 replicates, and experiments were performed on at least two separate occasions. Proliferation is shown as a percentage of 
DMSO control per cell line; error bars represent standard deviation between replicates. Statistical significance was determined across doses per cell line 
by single factor AnOVA; #P , 0.005. Statistical significance of each treatment versus control was determined per cell line by student’s t-test, *P , 0.05, 
**P , 0.005. (B) Breast cancer cells and MCF10A were treated with DMSO control or delphinidin at 25 µg/mL or 50 µg/mL. After 48 h, DnA fragmenta-
tion was measured using the Cell Death Detection eLiSA kit (Roche; indianapolis, in). each treatment group was done in duplicate. Fold change in DnA 
fragmentation is shown as a percentage of the control per cell line; error bars represent standard deviation between duplicates. Statistical significance 
of differences in DnA fragmentation was determined across doses per cell line by single factor AnOVA; #P , 0.05, ##P , 0.005. Statistical significance of 
each treatment versus control was determined per cell line by student’s t-test, *P , 0.05, **P , 0.005. (c) Cells were treated with 25, 50, or 100 µg/mL 
delphinidin for 48 h, or with DMSO at a volume equivalent to that in 100 µg/mL delphinidin as a control. Lysates were blotted for survivin anti-apoptotic 
protein; actin served as a loading control.Ozbay and nahta
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be more   significantly affected than PI3K signaling, 
  suggesting possible selectivity of delphinidin against 
the HER2-MAPK signaling axis versus HER2-PI3K 
signaling. Similarly, a short time course of delphini-
din  treatment  (50  µg/mL)  in  the  HCC1806  triple 
negative breast cancer line showed that phosphory-
lation of Erk1/2 was inhibited without any effect on 
Akt  phosphorylation  (Fig.  3B).  Phosphorylation  of 
MAPK proteins p38 and JNK were also unaffected 
by delphinidin, suggesting that delphinidin may spe-
cifically block downstream signaling through Erk1/2. 
Treatment of triple negative MDA468 breast cancer 
cells with 50 µg/mL delphinidin also inhibited phos-
phorylation of Erk1/2 without effect on Akt (Fig. 3C). 
Inhibition  of  Erk1/2  phosphorylation  occurred  as 
early  as  30  min  post-treatment  and  was  sustained 
over a 24 h time course. Thus, delphinidin suppressed 
HER2   signaling in HER2-overexpressing breast can-
cer  cells,  and    inhibited  Erk1/2  phosphorylation  in 
HER2-overexpressing and triple negative breast can-
cer cells.
Delphinidin inhibits survival of chemically 
transformed eR-negative MCF10A cells
To better examine the anti-cancer effects of del-
phinidin, we chemically transformed the MCF10A 
breast epithelial cell line by treating cells chronically 
with 100 nM of the dietary carcinogen PhIP, which 
has been shown to induce mammary carcinoma in 
rats.15 After 3 months of PhIP exposure, duplicate 
cultures  of  MCF10A.PhIP  cells  and  correspond-
ing control DMSO-maintained MCF10A cells were 
grown in matrigel for 4–6 weeks. MCF10A.PhIP 
cells were either treated with 50 µg/mL   delphinidin 
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Figure 2. Delphinidin blocks anchorage-independent growth and migration of breast cancer cells. (A) Cells were plated in matrigel and treated with   
50 µg/mL or 100 µg/mL delphinidin; control cells were treated with DMSO at the same volume as that found in the highest dose of delphinidin. Cells were 
maintained for 3–4 weeks, at which point photos were taken with an Olympus iX50 microscope at 4× magnification. Matrigel was then dissolved with dis-
pase (5 mg/mL), and viable cells were counted by trypan blue exclusion. Cell survival is shown as a percentage of DMSO control cultures; error bars rep-
resent standard deviation between replicates. Statistical significance between doses including control was determined per cell line by single factor ANOVA;   
#P , 0.05, ##P , 0.005. Statistical significance between cell lines was determined by single factor ANOVA. Statistical significance of each treatment versus 
control was determined per cell line by student’s t-test, *P  0.05, **P , 0.005. (B) Confluent cultures of SKBR3 cells were scratched down the center with 
a pipet tip. Cells were then treated with 50 µg/mL delphinidin or DMSO control. Photos were taken with an Olympus iX50 microscope at 4× magnification 
at 0 h and 48 h after treatment. growth inhibitory effects of delphinidin in breast cancer
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or  DMSO.  MCF10A.DMSO  cells  formed  very 
few  colonies  (Fig.  4A),  consistent  with  the  fact 
that this cell line is not transformed. In contrast, 
MCF10A.PhIP cells showed significant anchorage-
  independent colony formation, indicating that PhIP 
had transformed MCF10A cells, with 6-fold higher 
colony counts versus MCF10A.DMSO (Fig. 4B). 
  Importantly,    delphinidin  treatment    suppressed 
growth of MCF10A.PhIP cells. Thus, delphinidin 
inhibited  anchorage-independent  growth  of  the 
chemically  transformed  MCF10A.PhIP  cell  line. 
To determine if ER status of MCF10A cells had 
changed  after  PhIP  exposure,  MCF10A  parental, 
DMSO    control,  and  PhIP-transformed  cells  were 
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Figure 3. Delphinidin inhibits heR2 and MAPK signaling in breast cancer cells. (A) SKBR3 cells were treated with 50 µg/mL delphinidin for 6, 24, or 48 h. 
(B) hCC1806 cells were treated with 50 µg/mL delphinidin for 1, 5, 15, or 30 min. Control cells were treated with DMSO at the volume found in this con-
centration of delphinidin for the longest time point (48 h in (A) or 30 min in (B)). Total protein lysates were immunoblotted for (A) phosphorylated and total 
heR2, Akt, and erk1/2, or (B) p-Akt, total Akt, p-erk1/2, total erk1/2, p-JnK MAPK, and p-p38 MAPK; actin served as a loading control. (c) MDA468 cells 
were treated with 50 µg/mL delphinidin for 0.5, 3, 6, or 24 h. Control cells were treated with DMSO at the volume equivalent to that in 50 µg/mL delphinidin 
for 24 h. Lysates were blotted for phosphorylated and total Akt and erk1/2; actin served as a loading control.Ozbay and nahta
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examined by Western blot for ER in comparison 
to ER-positive MCF-7 cells (Fig. 4C). PhIP expo-
sure did not alter ER expression. Finally, since PhIP 
was previously shown to mediate transformation by 
activating Erk1/2 signaling,16 MCF10A cells were 
stimulated  with  100  nM  PhIP  in  the  absence  or 
presence of delphinidin, and examined by   Western 
blotting  for  Erk1/2  phosphorylation  (Fig.  4D). 
While  PhIP  induced  phosphorylation  of  Erk1/2, 
co-treatment  with  delphinidin  prevented  activa-
tion of Erk1/2 signaling. Thus, while delphinidin 
showed limited activity in non-transformed paren-
tal  MCF10A  and  control  MCF10A.DMSO  cells, 
anchorage-  independent growth and Erk1/2 signal-
ing were significantly inhibited by delphinidin in 
PhIP-transformed MCF10A cells.
Combination delphinidin plus  
heR2-targeted therapy show  
potential antagonistic effects
Our  initial  data  suggested  that  delphinidin  inhibits 
HER2  signaling.  Since  delphinidin  is  a  major  bio-
active  component  of  some  complementary  cancer 
medicines, we examined the effect of combining del-
phinidin with the currently approved HER2-targeted 
drugs Herceptin and lapatinib in BT474 and SKBR3 
HER2-overexpressing breast cancer cells. Low doses 
of delphinidin (6, 12, or 24 µg/mL) and clinically rele-
vant concentrations of Herceptin (5, 10, or 20 µg/mL) 
and lapatinib (100, 200, or 400 nM) were used in these 
studies. MTS proliferation assays showed that BT474 
and SKBR3 cells were sensitive to Herceptin and lap-
atinib, but that addition of delphinidin did not   further 
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cells were counted by trypan blue exclusion. Cell survival is shown as a percentage of MCF10A.DMSO cells; error bars represent standard deviation 
between replicates. Statistical significance between delphinidin-treated MCF10A.PhIP cells versus control DMSO-treated MCF10A.PhIP cells was deter-
mined by student’s t-test; *P , 0.05. (c) MCF10A parental, DMSO control, and PhiP-transformed cells were Western blotted for expression of estrogen 
receptor using MCF-7 cell lysate as a positive control. (D) MCF10A cells were treated for 60 min with DMSO or 100 nM PhiP in the absence or presence 
of 25 µg/mL or 50 µg/mL delphinidin. Total protein lysates were immunoblotted for phosphorylated and total erk1/2.growth inhibitory effects of delphinidin in breast cancer
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inhibit  proliferation  (Fig.  5).  Instead,  addition  of 
  delphinidin significantly reduced the anti-  proliferative 
effect of Herceptin in BT474 (Fig. 5A) and SKBR3 
(Fig.  5C)  cell  lines.  Similarly,  delphinidin  reduced 
the anti-proliferative activity of lapatinib in BT474 
(Fig. 5B) and SKBR3 (Fig. 5D). Thus, there was not 
any apparent benefit to adding delphinidin to HER2-
targeted therapy; rather, delphinidin appeared to actu-
ally reduce efficacy of these approved breast cancer 
drugs. Thus, while single agent delphinidin showed 
activity in breast cancer cell lines, combination with 
currently approved targeted therapies must be exam-
ined closely to avoid potential drug antagonism.
Discussion
The  biological  effects  of  delphinidin  in  breast 
  cancer cell lines included inhibition of prolifera-
tion,  as  measured  by  MTS  assay,  and  increased 
apoptosis, as measured by DNA fragmentation and 
reduced survivin levels. Delphinidin did not pro-
mote cell death in non-transformed MCF10A breast 
epithelial cells. However, MCF10A cells that were 
chemically transformed by chronic exposure to the 
PhIP carcinogen were sensitive to the growth inhib-
itory action of delphinidin. The most pronounced 
biological  effects  of  delphinidin  included  inhibi-
tion  of  anchorage-independent  growth,    induction 
0
+−+
−
HCT
Delph +
Dose 1
+
20
40
60
%
 
p
r
o
l
i
f
e
r
a
t
i
o
n
80
100
120
+−+
−+
Dose 2
HCT + Delph
A BT474
+
+−+
−+
Dose 3
+
0
+−+
−
Lap
Delph+
Dose 1
+
20
40
60
%
 
p
r
o
l
i
f
e
r
a
t
i
o
n
80
100
120
+−+
−+
Dose 2
Lap + Delph
B BT474
+
+−+
##
*
##
*
##
*
##
*
##
*
##
* ##
*
##
*
## ## ##
−+
Dose 3
+
0
+−+
−
HCT
Delph +
Dose 1
+
20
40
60
%
 
p
r
o
l
i
f
e
r
a
t
i
o
n
80
100
120
+−+
−+
Dose 2
HCT + Delph
C SKBR3
+
+−+
−+
Dose 3
+
0
+−+
−
Lap
Delph+
Dose 1
+
20
40
60
%
 
p
r
o
l
i
f
e
r
a
t
i
o
n
80
100
120
+−+
−+
Dose 2
Lap + Delph
D SKBR3
+
+−+
−+
Dose 3
+
Figure 5. Delphinidin reduces anti-proliferative activity of heR2-targeted therapies: potential for drug antagonism. (A) BT474 cells were treated with 5, 10, 
or 20 µg/mL herceptin (hCT), 6, 12, or 24 µg/mL delphinidin (delph), or combination hCT + delph. (B) BT474 cells were treated with 100, 200, or 400 nM 
lapatinib (lap), 6, 12, or 24 μg/mL delphinidin (delph), or combination lap + delph. (c) SKBR3 cells were treated with 5, 10, or 20 µg/mL herceptin (hCT),   
6, 12, or 24 µg/mL delphinidin (delph), or combination hCT + delph. (D) SKBR3 cells were treated with 100, 200, or 400 nM lapatinib (lap), 6, 12, or 
24 µg/mL delphinidin (delph), or combination lap + delph. Control cells were treated with DMSO at the volume found in the highest concentration of del-
phinidin and/or lapatinib. After 6 d, MTS colorimetric assays were performed to measure cell proliferation.
notes: Values are expressed as a percentage of control DMSO group per line. error bars represent standard deviation between six replicates. Statistical 
significance of differences between treatment groups was determined by ANOVA; ##P<0.005. Statistical significance of each treatment versus control was 
determined per cell line by student’s t-test; *P  0.05.Ozbay and nahta
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of  apoptosis,  and  prevention  of  PhIP-mediated 
  transformation.  These  results  provide  compelling 
evidence that delphinidin specifically targets breast 
cancer cells without   non-specific toxicity to non-
cancerous breast   epithelial cells.
Our  data  suggested  that  delphinidin  reduced 
proliferation  of  triple  negative,  ER-positive,  and 
HER2-overexpressing  breast  cancer  molecular 
subtypes. Consistent with our results, delphinidin 
has been shown to inhibit proliferation of the ER-
positive  MCF7  breast  cancer  cell  line.17  Growth 
inhibition of ER-positive breast cancer may occur 
independent  of  ER-targeted  effects,  however,  as 
published data suggested that delphinidin does not 
reduce ER alpha or ER beta expression levels.17 
In fact, delphinidin-mediated inhibition of MAPK 
signaling may be a critical molecular mechanism 
of growth inhibition. We observed reduced Erk1/2 
phosphorylation  after  delphinidin  exposure  in 
triple negative HCC1806 and MDA468 cells and 
in  HER2-overexpressing  SKBR3  cells.  Reduced 
Erk1/2  signaling  has  been  reported  in  delphini-
din-treated A431 cells   downstream of EGFR and 
HER2  inhibition,14  consistent  with  our  data  in 
SKBR3 cells. We found that delphinidin did not 
reduce  phosphorylation  of  other  MAPK  proteins 
(p38 and JNK) in HCC1806 cells. However, del-
phinidin  has  previously  been  shown  to  inhibit 
UV-induced Erk1/2, p38, and JNK MAPK phospho-
rylation in mouse epidermal cells.13,18 In addition, 
delphinidin did not significantly block Akt phospho-
rylation in MDA468 or HCC1806 triple negative 
cells. In contrast, UV-induced Akt phosphorylation 
was reduced by delphinidin in epidermal cells.18 
Collectively, these results indicate that delphinidin 
targets the MAPK signaling pathway, but also sug-
gest that delphinidin has potential cell type-specific 
or context-specific molecular effects.
Cellular  transformation  by  carcinogens  that 
induce  MAPK  signaling  appears  to  be  inhibited 
by  delphinidin.  Kang  et  al13  showed  that  12-O-
tetradecanoylphorbol-13-acetate  (TPA)–induced 
neoplastic transformation of mouse epidermal cells 
was  blocked  by  delphinidin.  The  authors  found 
that  delphinidin  directly  blocked  TPA-induced 
phosphorylation  of  MEK-Erk1/2.  Similarly,  we 
found  that  the  carcinogen  PhIP  activated  Erk1/2 
phosphorylation,  consistent  with  past  findings.19 
  Delphinidin blocked PhIP-mediated Erk1/2 activa-
tion, and inhibited anchorage-independent growth 
of   PhIP-transformed MCF10A cells. PhIP is one of 
the most abundant heterocyclic amines consumed 
by humans in cooked meat and fish, and has been 
shown to have carcinogenic activity in the mam-
mary gland, colon, and prostate of rats.15,19–22 Natural 
antioxidant compounds such as those derived from 
green tea have been shown to block PhIP-mediated 
carcinogenesis.24 Our data further support the role 
of polyphenolic compounds such as delphinidin in 
blocking cellular transformation by environmental 
or diet-derived carcinogens such as PhIP.
Delphinidin-mediated  apoptosis  was  induced 
at  the  highest  levels  in  HER2-overexpressing  cell 
lines. Use of delphinidin in HER2-positive disease 
would possibly be limited to single agent treatment, 
however, since combining delphinidin with Hercep-
tin or lapatinib appeared to reduce efficacy of these 
currently  approved  HER2-targeted  therapies.  Our 
molecular  data  indicated  that  delphinidin  inhibits 
HER2  signaling.  Similarly,  delphinidin  has  been 
reported to be a potent inhibitor of EGFR and HER2 
phosphorylation in the human vulva carcinoma cell 
line A431.14,23,24 Inhibition of HER2 signaling may 
be an important growth inhibitory mechanism of del-
phinidin in HER2-overexpressing breast cancer since 
these cancers have oncogenic addiction to HER2, and 
since  the  combination  of  delphinidin  with  HER2-
targeted drugs did not show synergy. If delphinidin 
affected multiple signaling pathways independently 
of HER2, we might expect synergy between HER2 
inhibitors and delphinidin since multiple molecular 
pathways would be blocked. Instead, the combina-
tion did not produce additive or synergistic effects, 
but yielded slightly antagonistic effects. Thus, del-
phinidin-mediated HER2 inhibition is likely to be 
an important molecular effect of delphinidin in this 
breast cancer subtype.
Based on our data, delphinidin may serve as an 
important  lead  compound  for  developing  novel 
therapies for breast cancer. The concentrations of 
delphinidin that we used in this study were in the 
µg/mL  range. These  are  likely  to  be  physiologi-
cally  tolerable  doses  as  humans  are  estimated  to 
consume  between  80–215  mg  of  anthocyanidins growth inhibitory effects of delphinidin in breast cancer
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daily,25,26  with  delphinidin  being  a  major  source 
of  anthocyanidins.  Delphinidin  has  demonstrated 
anti-inflammatory  and  anti-angiogenic  activities 
in  prostate  cancer  models,7  and  appears  to  be  a 
broad-spectrum  inhibitor  of  multiple  kinase  sig-
naling pathways including HER2 and downstream 
MAPK in multiple cell types.13,23,24 Our own data 
indicates that delphinidin is an inhibitor of HER2 
and Erk1/2 signaling, with growth inhibition and 
apoptosis observed in multiple molecular subtypes 
of breast cancer. Thus, delphinidin could represent 
a novel lead agent for development of future breast 
cancer chemotherapeutic drugs.
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